more_reports

Streetwise Articles



CRO Firm's Shares Rise on Q3 Earnings and Growth Prospects
Source: Streetwise Reports  (10/26/22)
Shares of full-service clinical contract research organization Medpace Holdings Inc. traded 37% higher yesterday after the company reported Q3/22 financial results that included a nearly 30% YoY increase in revenue. More >


Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results
Source: Streetwise Reports  (10/25/22)
Shares of Vaxcyte Inc. traded 61% higher yesterday to a new 52-week high after the company reported positive topline results from its Phase 1/2 study of VAX-24, its novel 24-valent pneumococcal conjugate vaccine candidate being developed to prevent invasive pneumococcal disease in adults 18 to 64 years of age. More >


Expert Says Buy Pharma Co. Stock 'as Soon as Possible'
Source: Clive Maund  (10/25/22)
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy its stock. More >


Biopharma Co. Shows Large Potential Return
Source: Dr. Joseph Pantginis   (10/21/22)
Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report. More >


Robotic Surgical Device Co.'s Shares Rise on Q3 Earnings
Source: Streetwise Reports  (10/20/22)
Shares of Intuitive Surgical Inc. traded 9% higher yesterday after the robotic surgical device maker reported Q3/22 earnings that included an 11% YoY increase in revenue and a 13% YoY increase in its installed da Vinci Surgical System base. More >


Companies Use Blockchain To Connect Hemp Growers, Consumers
Source: Streetwise Reports  (10/19/22)
Industrial hemp is legal in all 50 states, and companies are working to get CBD, insulation, textiles, and biofuel made from it to the masses. These three companies hope their partnership will help connect the growers and buyers. More >


Biotech Co.'s Target Price Over Three Times Current
Source: Dr. Joseph Pantginis   (10/13/22)
Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current. More >


Biopharma Co. Partners With Merck for Combo Drug Trial
Source: Dr. Joseph Pantginis  (10/12/22)
With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report. More >


Biopharma Co.'s Shares Roll to New 52-Week High Price
Source: Streetwise Reports  (10/12/22)
Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company reported positive topline data from its Phase 1 DC-806 Psoriasis study. More >


Chen Reveals His Picks for Last Quarter
Source: Streetwise Reports  (10/11/22)
Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies. More >


US Firm Teams up With Leading Pharma Co. To Delay T1D Onset
Source: Streetwise Reports  (10/7/22)
Provention Bio Inc.'s shares traded 25% higher yesterday after the company reported it is joining forces with Sanofi U.S. to support the potential upcoming U.S. launch of its teplizumab for use in delaying the onset of clinical type 1 diabetes in at-risk patients. The U.S. FDA is expected to rule on the firm's Biologics License Application in mid-November 2022. More >


Biopharma Target Price 10 Times Current
Source: Dr. Elemer Piros  (10/6/22)
Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current. More >


Biotech Co.'s Drug Showing 'Early Signs of Benefit'
Source: Dr. Elemer Piros  (10/6/22)
With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report. More >


Trial Results of New Drug for An Eye Disease 'Encouraging'
Source: Dr. Yale Jen  (10/6/22)
The data suggest this treatment could be safer and more effective in treating proliferative vitreoretinopathy than compounded methotrexate, noted a Laidlaw & Co. report. More >


Co. Uses RNA Editing as Treatment for Rare Disease
Source: Andrew Fein  (10/3/22)
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report. More >


Interim Results From Phase 2b Trial Are 'Encouraging'
Source: Dr. Elemer Piros  (9/30/22)
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report. More >


Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial
Source: Streetwise Reports  (9/30/22)
Shares of oncology-focused biopharmaceutical company Immuneering Corp. traded 9% higher after the firm reported it received U.S. FDA clearance for its IND Application for a Phase 1/2a clinical trial of IMM-1-104 for use in treatment of advanced solid tumors with RAS mutations. The company expects to enroll the first patient in the study in Q4/22. More >


Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial
Source: Streetwise Reports  (9/29/22)
Shares of Eisai Co. Ltd. traded 58% higher yesterday after the company reported topline data from its global Phase 3 clinical study demonstrating that its lecanemab significantly met the primary and key secondary endpoints in reducing mild cognitive impairment due to Alzheimer's disease. More >


Biopharma Asks for Emergent Use in US of New COVID Drug
Source: Edward White  (9/29/22)
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report. More >


Oncology Co.'s Shares Erupt on Signing Global License Deal
Source: Streetwise Reports  (9/27/22)
Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with Seagen Inc. to advance its LAVA-1223, a preclinical gamma delta bispecific T cell engager designed for use in the treatment of EGFR-expressing solid tumors. More >


Opportunity for Investors Found in Psychedelics Space
Source: Patrick R. Trucchio  (9/27/22)
Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report. More >


US Biotech Firm Keeps Growing Revenue
Source: Scott Henry  (9/26/22)
Revenue last quarter was strong, and management expects to increase revenue 20% this fiscal year, noted a ROTH Capital Partners report. More >


Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating
Source: Dr. Joseph Pantginis  (9/23/22)
To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report. More >


Analyst Says Buy Before Biotech Co.'s Clinical Trials
Source: Dr. David Nierengarten  (9/23/22)
Argenx SE has "several upcoming catalysts," noted a Wedbush report. More >


Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World
Source: Streetwise Reports  (9/21/22)
The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc. More >


Showing Results: 426 to 450 of 2681 Prev Next

Notable Quotes

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts